Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Study sponsor: ALX Oncology Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-03-03Actual
Enrollment · participants172Actual
Source updated2025-08-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.